Auna S.A. (AUNA) Earnings Call Transcript
March 11, 2026
Earnings Call Speaker Segments
Thanks, operator. Hello everyone, and thanks for joining Auna's conference call, where we'll review how we performed in the fourth quarter and across the full year. A quick note: there's a webcast presentation you can follow along with as we speak. That presentation is available on our Investor Relations website, or you can get in touch with Auna's Investor Relations team if you'd like a copy. Also, when we discuss variances, keep in mind those are year over year, and they're in FX neutral or local currency terms for Mexico and Colombia, unless we state otherwise. Let's move to Slide 2. In addition to sharing unaudited results prepared according to international financial reporting standards, our discussion will touch on certain non-IFRS financial measures and operating metrics, among them foreign exchange neutral calculations. We ask investors to take a close look at how these measures and metrics are defined in the earnings press release we issued yesterday, so that they grasp what those terms mean. These non-IFRS financial measures and operating metrics ought not to be considered in isolation, nor treated as a substitute for, or as superior to, IFRS financial measures — they are supplied solely as additional information. Ahead of our prepared comments, we want to note that certain things said in today’s conversation may constitute forward-looking statements. These reflect what management presently expects and believes, and they carry various risks and uncertainties that could lead actual outcomes to differ significantly—including circumstances beyond the company’s ability to control. The following items are examples of forward-looking statements, though there are others: our target leverage ratio; when the problems involving physicians, suppliers, and information systems in Mexico are expected to be resolved; what the key initiatives we are carrying out in Mexico, Colombia, and Peru will produce; the capacity and market that Torre Trecca is expected to have after construction; how our strategic plan will be executed, which covers restoring our growth levels and introducing AunaWay in Mexico; the investments we intend to make in Mexico; our guidance for revenue growth and EBITDA; and how additional growth and sustainable value will be generated for every stakeholder. These risks are described in our Form 20-F filing with the U.S. Securities and Exchange Commission and in our earnings press release. Let's move to Slide 3. On the line with us for this discussion are Suso Zamora, who serves as Executive Chairman and President; Gisele Remy, our Chief Financial Officer and Executive Vice President; plus Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets. Their remarks will address Auna's financial and operating results on both a consolidated and segment basis for the fourth quarter as well as the full year, and they will additionally share updates regarding our numerous strategic growth initiatives. Following that, the call will be opened for your questions. Suso, the floor is yours.
Thanks, Annie. Good morning, everyone, and I appreciate you being here as we go through our results for 2025. In Q4, we got our Mexico business back on stable footing, and it's now clearly positioned to deliver consistent growth in both revenue and EBITDA during 2026. With the new leadership group we've put in place in Mexico, our efforts have centered on reaching more of the privately insured family segment, which is larger, and on deepening our ties with specific physician groups. Because these steps came together late in the year, they weren't enough to make up for the volume we lost earlier in 2025, so the year as a whole came in below our expectations. Signs that Mexico is improving include Auna once more being part of the policies covering the bigger portion of the privately insured market, and also an award to extend a healthcare plan on an exclusive basis for most services with ISSSTELEON, the social security institution that covers every state employee in Nuevo Leon. Over in Peru, the quarter brought continued outperformance that anchored Auna's results overall, mainly thanks to a favorable pricing mix in healthcare services and a record low medical loss ratio. Peru benefits from operational scale and plenty of room left to grow. As we shared recently, we reached an agreement with EsSalud using a public-private partnership structure to renovate and run a 600,000 square foot high complexity outpatient facility located in Lima, which will broaden care access for roughly 3 million patients that EsSalud serves today. In Colombia, results matched what we set out to achieve — growing while also improving cash flow through a greater share of risk-sharing contracts and less dependence on intervened payors; these outcomes look encouraging. On a consolidated basis, adjusted net income for the quarter came to PEN 136 million, up from PEN 36 million in the comparable quarter a year ago. Across the full year, adjusted net income grew more than threefold, reaching PEN 336 million. We also made Auna's capital structure stronger in the quarter by refinancing $825 million of debt, which gave us a better maturity profile and brought interest expense down. Even with the premiums and costs tied to that refinancing, our leverage ratio stayed at 3.6x, helped by robust free cash flow generation that lifted our cash position by 42%. Now let's turn to our consolidated results on Slide 5. Peru's strong showing and Colombia's resilience offset the setbacks Mexico faced last year, and Mexico is now in a good position to recover strongly this year. Consolidated revenue rose 6%, FX neutral, for the quarter, while adjusted EBITDA fell 14%, FX neutral, largely due to Mexico's weak performance plus an unfavorable year-over-year comparison in Colombia tied to extraordinary items booked in the prior year quarter. For the full year, revenue was up 4%, while EBITDA was down 3%. As you can see in the bottom half of the slide, capacity utilization in healthcare services fell 2.3 percentage points to 64%, which reflects lower utilization, especially in Colombia, as we work to lessen dependence on intervened payors. In Peru, Oncosalud's planned memberships rose 4.4%, and the oncology MLR kept getting better, hitting an all-time low of 48.5%. Now let's turn to segment results, starting with Mexico on Slide 7. Thanks to deeper integration of Opcion Oncologia and in part to the debut of our new Oncocenter at Doctors Hospital, Oncology revenues climbed once more in the fourth quarter, up 35% from the prior quarter. Significantly, Out-of-Pocket revenues rose as well, accounting for 12% of total revenues in Mexico in December. This expansion signals the early phase of Mexico's recovery and helped counterbalance a portion of the legacy volume and margin pressures tied to physician and supplier relationships that we are steadily leaving behind; we anticipate that our oncology growth initiatives will keep building momentum in 2026 as the Oncocenter becomes more fully integrated into our healthcare network in Mexico. Market conditions stayed weak in Mexico, weighing on the volume of surgeries and emergency visits and driving a 3% drop in fourth quarter revenues in local currency. Still, it's worth emphasizing that revenues held flat versus the prior quarter, which speaks to our operations stabilizing. On the right side of the slide, you can see fourth quarter adjusted EBITDA fell 36% and was down 18% for the full year. This stemmed from lower revenues across the year and reduced profitability in the final quarter, driven by higher costs and thinner margins under our prior healthcare plan with ISSSTELEON; on Slide 8, we share an update on the many initiatives in motion to get us back on track toward these goals; we have bolstered our leadership team in Mexico with the commercial, operational and clinical experience and skill set needed to lead Mexico; and with that stronger team, we have carried out highly effective actions that leave us confident we have turned our Mexico operations around. The team features a new Chief Medical Officer, who is helping deepen physician engagement, lift productivity and enhance medical outcomes throughout our facilities. These steps put us in a strong position to return to growth in 2026. The fourth quarter results made the turnaround of our Mexico operations clear. I'd point to the addition of our hospital network to the preferred provider tiers, policies covering the bigger portions of the privately insured population and the introduction of multiple packaged services to better reach various market segments, especially the Out-of-Pocket segment. Via targeted pricing efforts and prenegotiated physician rates, this high-margin segment accounted for 12% of revenues in Mexico in December, up from 8% in the third quarter. Corporates and government agencies offer yet another key opportunity. The strategy's most immediate effect was extending the healthcare plan to cover, on an exclusive basis for most services, ISSSTELEON, the social security institution that covers all state employees of the state of Nuevo Leon, which yielded a double-digit price increase for the year. We are right now in talks with additional governmental agencies. As noted earlier, we entered the preferred tier with 2 major insurers, which ought to drive higher patient volumes ahead. We've additionally entered into an arrangement with a major insurance provider to steer policyholders toward Auna's oncology offerings via focused deductible frameworks and financial inducements. That should assist us in scaling our oncology business even more, encompassing the Oncocenter Monterrey, where we intend to double the medical staff during this year. Engagement and productivity among physicians keep rising. And in the quarter, we verified gains in volume and margin from roughly 250 physicians, who represent around 80% of revenues within the hospital network. Such alignment incentives underpin greater productivity, better clinical results and stronger operating performance. Let's go to Slide 9 to talk about how Peru performed. Running at scale, Peru keeps surpassing expectations in revenue as well as EBITDA. Revenue rose 11% in the quarter, propelled by expansion in high complexity services that raised the average ticket, along with greater volumes backed by investments in new medical equipment, added bed capacity and focused marketing efforts. On the insurance front, Oncosalud's revenues climbed 10%, aided by a 4% rise in planned memberships and yearly price adjustments. Oncology's MLR likewise fell 4.4 percentage points to 48.5%, marking a sixth straight quarterly drop in the MLR. That gain came from a mix of higher tickets and ongoing moderation in pharmaceutical costs. Total adjusted EBITDA rose 14% during the quarter and 14% for the full year. As we deepen our reach into Peru's healthcare market and broaden relationships, we anticipate this segment of our regional platform will stay a key growth driver ahead. Now let's shift to Colombia on Slide 10. In the quarter, we limited our services to government intervened payors and thereby effectively handled the risks they presented in our accounts receivables, and that produced a healthy cash cycle in Colombia. Furthermore, we broadened risk-sharing models like PGP, which rose 4 percentage points to account for 21% of segment revenue. Higher tickets along with surgeries and emergency treatment more than compensated for lower volumes, backed by growth in chemotherapy and imaging. Moreover, serving the patient population of a new payor and the expansion of PGP added to a 6% rise in Colombia revenue for the quarter. For the full year, revenue grew 4%, chiefly fueled by higher tickets. The declines in adjusted EBITDA and margins displayed on the right side of the slide mirror an unfavorable comparison with the fourth quarter of 2024, which gained from extraordinary price adjustments and the year-end recognition of procurement rebates. That wraps up my review of the quarter and the year. I'll now hand the call to Gisele, who will go over our results in more detail.
Thanks, Suso. On Slide 12, the chart makes clear that having a diverse set of regional platforms let Auna achieve 6% top-line expansion during the quarter, and 4% across the full year. Within the quarter, growth of 11% in Peru together with 6% in Colombia more than compensated for the 3% contraction in Mexico, a market where our operational results have become more consistent. Even though demand there is still weak, the business we've built in that country has laid a solid groundwork for profitable growth both this year and afterward, as Suso described earlier. Let's move on to Slide 13, if you would. Adjusted EBITDA for the fourth quarter fell 14% on an FX-neutral basis to PEN 220 million, while the margin shrank 4.5 percentage points, landing at 19.5%. Gains in both margin and EBITDA from our Peru operations were outweighed by the margin reduction in Mexico tied to service and specialty mix, the prior healthcare plan covering ISSSTELEON, and the steps we're taking to strengthen Mexican operations via leadership changes and new IT systems. Two additional factors pushed quarterly EBITDA lower: a larger share of risk-sharing contracts in Colombia, plus the rebates booked during last year's fourth quarter in Colombia, which made for an unfavorable comparison against the prior year. If you strip out the extraordinary effects from both periods, Colombia's fourth-quarter 2025 EBITDA would have come in roughly flat relative to the fourth quarter of 2024. Slide 14, please. For the full year, adjusted EBITDA was fairly unchanged, down 3% in FX neutral to PEN 917 million, and margin slipped 1.7 percentage points to slightly below 21%. That EBITDA trajectory stemmed mostly from the identical factors I walked through for the fourth quarter. Let's turn now to Slide 15. Our adjusted net income rose by over 3x in the fourth quarter, helped along by noncash FX gains; this slide lays out how the year-over-year change breaks down. Operating income sits at the far left of the bridge. Its PEN 46 million drop came chiefly from Mexico's weaker quarter, plus the unusual pricing Colombia enjoyed during last year's same quarter. The favorable PEN 71 million noncash FX swing stems mainly from the Peruvian sol strengthening versus the U.S. dollar beyond the band of the call spreads we previously had in place. That PEN 154 million shift in net interest expenses shown at the center of the bridge resulted mostly from PEN 170 million in extraordinary costs tied to our refinancing — encompassing the tender premiums we paid, plus noncash accounting effects from derivative unwinds and rollovers used to properly hedge the newly issued instruments, along with recognition of unamortized costs from the prior term loan that got repaid; those effects also form part of the PEN 187 million in extraordinary items and adjustments, together with the incentive payments tied to the Opcion Oncologia doctors. The PEN 41 million figure for less income taxes ties back to a negative pretax profit during the quarter, which came from the extraordinary refinancing impacts and produced an income tax credit. Let's turn to Slide 16. On a full-year basis, adjusted net income rose, reflecting stronger financial discipline along with the actions we took to strengthen Auna's debt structure. The PEN 158 million drop in operating profit stemmed mainly from the Mexico stabilization I mentioned earlier. The PEN 235 million FX variance represents a positive noncash amount of PEN 193 million in 2025 versus a negative PEN 42 million impact in 2024, and it relates to the Peruvian sol's appreciation, as I noted earlier. It's worth highlighting that after the refinancing, we moved the range on the Peruvian sol call spread hedges nearer to current FX levels, so these swings likely won't appear in 2026. The PEN 62 million rise in net interest expense came largely from the extraordinary expenses tied to the refinancing. Importantly, if you set aside net finance costs from exchange rate differences and extraordinary refinancing costs, net finance costs would have reached PEN 459 million for the full year 2025 and PEN 561 million for the full year 2024, a decrease of PEN 102 million, or 18.2%. The PEN 205 million in noncash and extraordinary items mostly reflects the partial repayment of the 2029 notes, plus a PEN 24 million adjustment to business development expenses in the first quarter of 2025 tied to payments to the Opcion Oncologia doctors. Finally on this slide, the PEN 29 million rise in income tax simply mirrors higher pretax profit in 2025. The 2025 effective tax rate took an unfavorable hit from the refinancing exercise in the fourth quarter. Excluding the refinancing impacts, our effective tax rate would have come in largely in line with statutory rates and inside our target range of 35% to 40%. Let's now go to the cash flow bridge on Slide 17. Free cash flow rose 35% to PEN 582 million, while our year-end cash position climbed 42% to PEN 335 million; that gives us sufficient funds to keep investing in our strategic growth initiatives in Mexico and Peru. Pretax operating cash flow was up nearly 2% on better cash conversion. Organic maintenance CapEx came to PEN 145 million, or 3.3% of revenues. This was mostly made up of PEN 86 million of infrastructure CapEx, PEN 51 million for the implementation of SAP and Hospital Information Systems in Monterrey, and PEN 15 million of the OCA holdback obligations. Free cash flow also got a boost from PEN 76 million of cash arising from a rebalancing of the Auna Seguros investment portfolio. The PEN 454 million in interest paid, which net of refinancing fees would have been PEN 407 million, reflects a decrease of almost PEN 90 million versus the PEN 498 million in interest paid in the 12-month period of 2024, also net of extraordinary items. What we're seeing here is a substantial decrease in interest expense alongside better interest coverage, and that puts Auna in a strong spot to keep paying down debt as we move through 2026, supported by rising cash flows and lower interest costs; let me now say a few things regarding Auna's updated debt structure, which you can find on Slide 18. Through our refinancing of debt totaling PEN 825 million equivalent, we've considerably strengthened Auna's capital structure — lowering interest expense, lengthening our maturity profile, boosting short-term liquidity, and because of that, releasing a significant share of our short-term revolving credit facilities. Let me emphasize once more that if you set aside the premiums and expenses tied to the 2025 refinancing, we did produce cash after making interest payments during 2025, and we're in a good position to grow that cash generation in 2026. Lastly, every one of these effects has brought us nearer to reaching our medium-term target leverage ratio of 3x net debt-to-EBITDA; that brings my review to a close. I'll hand the call back over to Suso, who wants to finish up our presentation prior to opening the call for questions.
Thank you, Gisele. I'd like to wrap up by highlighting several important points. We entered 2026 in a strong position, from both an operational and a financial standpoint. Our fresh leadership group in Mexico has a well-defined route to expansion, and the measures we've taken to mitigate risk in Colombia keep safeguarding our cash cycle, while Peru remains the foundation of Auna's vertically integrated platform, showcasing how sturdy and predictable our business model is at scale. Bringing in things like Centro Ambulatorio Trecca will widen the market we can reach in Peru even more and underscores the considerable opportunities for growth that still lie ahead, as does our PGP expansion in Colombia and the ISSSTELEON healthcare plan award in Monterrey. When it comes to Colombia, we'll keep diversifying away from intervened payors and put cash flows first through PGP arrangements. We anticipate Mexico bouncing back in 2026, recovering volumes along with margins. The team has widened Auna's accessibility for more policyholders and coverage plans, whether through private insurance companies, employer groups or ISSSTELEON. Last, we started the year with better liquidity and the financial flexibility required to carry out our growth strategy. Before we get to guidance, as trading volumes pick up and our commercial and operational initiatives and high complexity build momentum, we anticipate Auna's share price will better mirror the intrinsic value of our platform. We'll keep deepening our engagement with the investment community so there's a greater understanding of what Auna is and what it can become going forward. Now, let's move to guidance on Slide 20. Bearing in mind the market conditions we expect this year, our improved standing in Mexico and Auna's reinforced capital structure, we anticipate adjusted EBITDA rising 12% FX-neutral, backed by disciplined cost management and continued investments in our strategic growth initiatives. We're also forecasting revenue growth of 12%, fueled by sustained commercial momentum and operational execution. And lastly, we expect CapEx to stay at roughly 4% of revenue as we keep balancing growth investments against cash flow generation. With that, we'll open up the call for questions. Thank you so much.
We were hoping to dig a bit deeper into your guidance. And if you could give us a finer breakdown by region or by business line, what growth and EBITDA expansion are you seeing in each one? Our assumption is that the recovery in Mexico is the main driver behind most of this year-on-year improvement. But if that's the case, shouldn't we be looking for somewhat more on the margin side, particularly given that the revenue and adjusted EBITDA guidance point to margins staying flat? Yet if Mexico is bouncing back, and that's a fixed business segment for the company, shouldn't we be looking for somewhat more in EBITDA growth relative to revenue growth? And a second question, also about the guidance: what risks surround your 2026 guidance? Where do you think things might go wrong? And how are you evaluating that?
Good morning, everyone, and thanks for joining the call. Let me — it's a long question and it's a long response. Let me tackle it in this manner. To begin with, on Mexico, Mexico has had a solid start to the year, consistent with what we expected and with everything we accomplished in 2025; so January and February 2026 versus 2025 metrics, I see improvement across a number of different lines. I mean surgery is growing at a single-digit rate <<inaudible>> are growing at a double-digit rate; and naturally, in oncology, radiotherapy and chemotherapy, growing at a double to triple-digit rate; and naturally, extremely high compared with last year, since Opcion Oncologia wasn't there. Occupancy utilization in Mexico, we also see, is trending upward. In February, I see it hitting 41%. So all in all, Mexico's results, revenues are growing at a high single-digit rate compared with the same period a year earlier. Naturally, ISSSTELEON is only just ramping up its volume. So I'm excited about this; regarding margin, and I'll get to guidance, but regarding margin, as Gisele also remarked on that. So Mexico's EBITDA margin mirrors the mix of services and specialties, and I'm speaking about 2025. As we look at 2026, with ISSSTELEON expanding, with preferred provider status now in place, and with all our cost containment strategies that we also mentioned in the earnings release, we anticipate higher volumes and margin gains in 2026. Naturally, as noted earlier, we see interesting and very promising growth in oncology. And naturally, those are businesses where we have cost containment. And then regarding guidance, to wrap up the question. First of all, in terms of what might prevent or delay us from achieving the guidance. I think last year, we weren't comfortable because there were many externalities. And that's the reason we didn't provide guidance. The political headwind in Colombia, the issues we had in Mexico as well. At this point, taking into account every initiative and how we've turned these difficulties into advantages, I'd say our confidence in the company's steadiness and its prospects is quite high, and the guidance sits very well with us. Naturally, the key unknowns are still there: how quickly volume will recover in Mexico — which, as I noted earlier, we expect to keep expanding — along with macroeconomic circumstances in the countries where we operate, though on that score Mexico looks fairly steady to us. Then there are particular dynamics surrounding payers, which in my view could actually work in our favor. With Peru still delivering strong results and Mexico well along the path back to health, I have strong conviction that the guidance can be met. Gisele, I'm not sure — is there anything you'd like to add regarding this rather open-ended question?
Absolutely, Suso — thanks for asking that. I suppose the thing I'd add is this: how does that guidance break down by country? And on the margin side, what do we anticipate? Typically, whenever we lay out our growth objectives, the balance across the 3 geographies is really strong. So off the back of every strategic initiative we discussed during this call, we anticipate robust growth from each of those 3 geographies. As for margins, when it comes specifically to Mexico — as we pointed out during the call, the fourth quarter, that effect weighed on the margin for the fourth quarter — but we'll see that margin bounce back in Mexico's case as we move into the first quarter of 2026 and through the remainder of the year, relative to where it stood in the fourth quarter, correct? So we'll see both a blend of EBITDA growth across those 3 geographies and all the strategic initiatives we're pursuing in Mexico's case as well, in order to keep costs in check and ultimately lift volumes, which clearly will also deliver a positive effect on margins.
So to wrap up, we aren't providing any guidance broken out by nation. That said, down the road we may well decide to do that. For the moment though, speaking in broad directional terms, when I look ahead at where this company sits 5 years from now, my expectation is that Mexico and Peru serve as its engines. Colombia's share will shrink as a result of expansion in Mexico and Peru; Colombia remains a vital piece of our strategy today; yet given its size, the cost efficiencies it delivers let us carry them over to the other 2 countries, while the opportunities for growth in Mexico and in Peru likewise keep being the leading sources of expansion across the coming 5 years.
I'd like to ask about Torre Trecca — there have been some recent updates on that. Could you give us more color and additional detail regarding margins and how much revenue it contributes? Also, does the company already have a fixed date for when the project opens — possibly Q3 or Q4 of 2028, unless I'm wrong about that. And then, just to go back over the ISSSTELEON price increase: you're anticipating a double-digit price increase for 2026. Is that right? That's all.
Thanks so much, Giovanni. Let me take the last question first — yes, that applies to the whole of 2026. It's a far better award than anything we've had before. It also lets us control prescription as well as devices. So both qualitatively and quantitatively, what I see is a substantially improved contract. I believe we'll provide excellent service to them, and we'll also enjoy attractive margins from a large contract — the biggest one possible when your counterparty is something like the state — in Nuevo Leon. So yes, that covers all of 2026. Now, turning to Torre Trecca, this should be seen as a highly attractive opportunity for Auna. Let me step back so the investor community is clear on this. Auna is a healthcare player that's had a lot of success in B2B relationships with an insurance company, obviously with large collective employers or groups, and then in Peru, especially on the B2C side. The largest market, when you look ahead over the next 10 years, is the B2G segment, with the state being the big payer for certain services. That exists everywhere around the globe, and it's a very attractive segment in Peru and in Mexico in particular as well. So this contract is also foundational for our expansion into the B2G segment. As for Torre Trecca, we no longer wish to call it Torre Trecca. The name we want is Centro Ambulatorio Trecca. It's an ambulatory center set to deliver 3 million services to the EsSalud population. EsSalud is Peru's social security system. And it's an ambulatory center heavily focused on a small number of services — those where EsSalud faces limitations in providing them — with a very well-known and very stable payment system through EsSalud, which involves issuing certain certificates for the operation each month. As for construction, while we make progress, EsSalud will issue those certificates. They're easily discountable in the market. There are implicit risks around public approval. And there's no payment risk. It's a private public partnership system that functions in Peru and has been proven over the last, I believe, more than 10 years. So there's no risk in them. There's no risk in payment. The contract is very solid and very focused, as I mentioned, on a very small number of services — 6 services. 6 clinical services, scaled. And yes, operation will begin in the second semester of 2028. And I can't give the numbers. And I think at present, what we see is that Centro Ambulatorio Trecca will account for something like 20%, 25% of our business in Peru once mature. It is a significant business. And more importantly, qualitatively, it's a segment where we haven't been present. People sometimes talk about the private sector in health care in Peru and its size and that it's growing, but it's growing — it's not growing as fast as the other segments. But this is a substantial new opportunity for Auna at a major scale, serving the principal payer in Peru. It is a very important opportunity for Auna, no doubt. I don't know, Gisele, if you want to add anything, if I've forgotten any parts of the question.
No, Suso, I think that's quite clear. I'd simply emphasize for everyone listening that spending on construction gets reimbursed via progress certificates, which EsSalud pays, and that greatly lowers the capital risk Auna faces. So it's entirely funded.
Also, we aren't the only public-private partnership in Peru with this kind of system. So what we're adopting is something proven and that has been functioning, as I mentioned earlier, for years in Peru.
Thank you, operator. Good morning to all of you. I'll start with the webcast questions. A number of these have already gotten responses. Even so, I'd like to give them a mention. So — and if Gisele or Suso wants to add anything further about those questions, or the answers, please feel free. If not, I can continue; so the first comes from <<inaudible>> and what he asks is, could you please provide more detail on the Torre Trecca project? Financing, operating, what's your perspective on it? And the second one concerns Trecca well, it's from Julio Lam. He graduated from Universidad de Piura. My question is related, do you have expected CapEx that will be invested in Torre Trecca during this year and the next one? And if there is, can it be watched?
Okay, let me just recap briefly, since there are two questions here. Once again, Centro Ambulatorio Trecca operates under a concession structure. That means revenue is predictable, backed by minimum guaranteed payments coming from EsSalud. Like Gisele mentioned, those construction costs are fully reimbursed through the progress certificates you brought up. Capital risk goes down because of this; it ties directly into the substantial unmet need for outpatient services in Lima; so we're capturing a very large portion of that unmet outpatient demand in Lima, and doing so in a way that's highly de-risked. Naturally, as things move forward, we'll gladly share the milestones we hit. And regarding — if it's there, can someone actually see it? I mean, obviously, it's a tower that's already standing. It's not completed yet, and we're going to refurbish it and finish it. So yes, obviously, we'll be sure to post photographs and images, both interior and exterior, as we make progress, and perhaps some virtual tours too. Let's note that down, Annie, please. Thank you.
Thanks, Suso. Christian Tesi will be asking the next question. What CapEx do you expect for 2026, and then for 2027 and 2028? I remember you spoke about growing the business. What CapEx would that involve?
Appreciate that, Annie. Sure — I can add a bit more detail around CapEx. Like Suso said earlier, our full-year guidance sits at roughly 4% of revenue. That's pretty consistent with prior years. The spending will go toward maintenance-type investments, covering medical equipment and infrastructure alike. It also covers our technology investments tied to the system rollouts we're still doing in Mexico and Colombia, plus the remainder of our recurring CapEx. We aren't providing specific guidance out into '27 or '28. However, as the question brought up, we'd expect work on expanding our Lima network to kick off in 2027, and we'll share more with the market on that as the year goes on.
Possibly, Annie, that's worth noting in connection with what Gisele just said. So occupancy at Lima is getting quite high. And as that becomes clear, we find ourselves weighing particular alternatives for growing urban ecosystem health care in Lima during 2027 and 2028.
Thanks. Suso. Christian Tesi has the next question. At what point do you anticipate Mexico's total occupancy rate hitting 40%?
Absolutely. I appreciate you asking that. As I noted when responding earlier, we are, I think, already sitting at 41%. On some particular days, particularly at Doctors Hospital — the primary facility we have in Monterrey for higher complexity care — I've observed rates considerably above that. So once more, I feel encouraged that we've surpassed 40% already; 41% is where we stand, and naturally, across the entire year, we keep seeing room to expand that further.
Thanks, Suso. Our next question is from Gerard Forte. On Colombia, what needs to happen for provisions to be reversed? Might that start to happen in the first half of 2026?
I appreciate that question, Gerard. Just like we've told the market before, an expected loss model is what drives our provisions. That holds true across all 3 of the geographies. When it comes to Colombia in particular, the expected loss model includes a distinct methodology for the intervened entities. Our provisioning continues to follow the expected loss model. While this doesn't signal a view that collection on those accounts won't happen, it does allow us to reduce risk on the balance sheet as well as on future results. We don't anticipate any reversions in impairments of accounts receivable during the first half of 2026.
Alexander Louis has the next question. I'll also combine it with the one from Temo Tarago. Both concern the Sojitz MOU. Is there anything new you can share regarding that Sojitz MOU?
Alright. In fact, over the past several weeks, we've been sitting down with Sojitz in Mexico and other locations, going over a range of options. I'd say we aren't at a point yet where we can share anything with the market, though I believe we're building momentum on that front. My view is that going forward, just as we've done before, we need to concentrate on expanding through acquisitions. Sojitz is putting forward a promising possible capital injection — one that would support our expansion, especially in Mexico; so we'll revisit that, but it ties back to Mexico, and it means directing additional dollars there and growing that market. And as soon as we've developed and sharpened it a bit further alongside Sojitz, we will absolutely take it back to the investor community; that will address Cameron Carrago's inquiry regarding Sojitz. I'm not sure, Gisele, that's where things stand as I see it. Any other items?
Correct. No, nothing to add on that end.
Alright, let’s keep going. Our next question is from Antonio Cardoso, and it has to do with our debt. After the refinancing, what is the all-in cost of debt?
Thanks for asking that. To start, I want to point out that following the refinancing we carried out in the prior year, we raised the share of funding obtained directly in local currency, and as a result — this came up earlier on this call — direct local currency funding now accounts for 56% of our total debt, while U.S. dollar-denominated debt makes up the other 44%. That said, derivatives hedge 85% of that U.S. dollar-denominated debt back into the Peruvian sol. You'll remember that our all-in rate naturally blends multiple currencies along with wherever rates stand across each of the 3 geographies. Under the old debt structure, our blended rate for 2025 came in at roughly 12.5%, and thanks to the refinancing, plus the new derivatives now in place to hedge the revised debt structure, that rate has fallen by more than 100 basis points — measured on a blended basis that captures all our debt, short term as well as long term.
Saguno Turkani is up next, and this one likewise touches on cash flow. Saguno Turkani offers congratulations on a robust close to 2025. Given that the business has now formally crossed into positive free cash flow inflection, and with guidance sitting at USD 45 million of free cash flow for 2026, how does the Board plan to rank its capital allocation priorities? More pointedly, since shares are changing hands well under book value, has there been any conversation internally about launching a share buyback program at the point when the leverage ratio reaches the 3x goal?
Appreciate that, Saguno — good question. I can't give you an exact figure, but the Board has been talking about how best to deploy capital, and about the various alternative allocations available to us. One thing worth pointing out: I believe we said this in the earnings release — our stock has underperformed dramatically, in our view, due to selling pressure from a very large shareholder that is now officially no longer a shareholder and has sold its position. So with no significant selling pressure coming from anyone, we think the shares will trade much better and certainly closer to book value. That said, to be clear, the Board has discussed — has analyzed buyback programs. Given that the selling pressure is now resolved, I'm not sure it would rank as a high priority. In my view, a higher priority would be using the balance sheet, once it's below 3, to keep growing at the same rate as in the past, especially in Mexico; in Mexico we have a very rich pipeline of growth opportunities, high complexity, higher margin opportunities, and that's where we need to direct the money to produce, I believe, more appreciation in the stock price. Gisele, would you like to complement my response?
Right. I'll just add to what Suso said on the first part of the question, regarding free cash flow and where we see things going. We haven't provided any particular guidance on free cash flow, but as Suso noted, we have issued robust guidance when it comes to revenue and EBITDA growth, and that clearly will flow directly into how much free cash flow we produce in 2026. On top of that, since we keep managing working capital with discipline, and given what I said earlier about CapEx figures — which during 2026 will stay near historical levels and be confined to maintenance plus IT investments — we anticipate free cash flow expanding, consistent with the revenue and EBITDA outlook we're guiding to. And because, as I mentioned before, we've brought interest expense down substantially, that creates a beneficial cycle when it comes to deleveraging. So I want to stress that during 2025 the company already demonstrated it could produce free cash flow — produce cash flow once interest payments were made — and that will only increase as we move through 2026, allowing us to keep deleveraging and move nearer to the 3x net debt-to-EBITDA target.
All right. Joaquin Vero has the next question. Thanks for asking it. What's your plan for phasing in higher occupancy over in Mexico, and how will margins recover to 30%? And what occupancy figure do you consider normal for 2026?
All right, thanks, Joaquin. So when it comes to those two things — how full our hospitals are and our margins — we've handled it largely by focusing on mix, specifically moving toward more complex cases. Sure, you could get a hospital filled up far more quickly, but the margins you'd get would be far thinner. That's why we're extremely deliberate about this. Filling a hospital while keeping margins elevated, though, requires a greater proportion of high-complexity work. That's precisely the approach we intend to take as we ramp occupancy in Mexico and, naturally, bring the margins back. Something I really want to stress: volume, and growth in volume, is the bedrock that supports everything else, including the more complex cases and, obviously, margins. So by being part of the significantly bigger health care plans across Monterrey, our total addressable market expands enormously when it comes to private policies. Volume growth will follow from that. Margin recovery, meanwhile, will come from mix — we have a very well-defined plan for 2026 to claw back at least a couple of points of the margin contraction we've put in place, ensuring we have a rising volume across all the services and treatments in our hospital network. So I don't believe we're providing guidance on where occupancy will land. Gisele, I firmly believe that the 40%, 41% we're at right now is a genuinely solid base, and we're going to grow it. We are absolutely going to grow it. I'm not sure, Gisele, should we say something about occupancy in Mexico?
I'd just like to chime in on Suso's points, looking at it through both occupancy and margin. As Suso mentioned, I want to remind the market that we've been granted the ISSSTELEON healthcare plan extension, and the economics on it are much better. We're entering the year holding preferred provider status with two of the big insurers. Talks with payers around cost containment have been central to locking in that preferred provider position, and that's going to directly drive higher volumes in 2026, along with margin improvement. And lastly, like Suso said, over the first two months of 2026 we've kept seeing growth in a number of services, utilization is normalizing, and the cost base is settling. So because of all that, we anticipate a gradual recovery through 2026.
Constanta Orbenetta has the next question. In Mexico during Q4, could you explain exactly how ISSSTE damaged your results? And in what way will the planned extension make things better for 2026?
Okay, thanks Constanta. Essentially, when it comes to the improvement from being awarded that ISSSTE contract for 2026, the main drivers are these: number one, our prices went up by 30%, and number two, we built in a provision giving us authority over prescriptions for pharma as well as devices. That matters enormously when it comes to containing costs and, naturally, to raising prices so we get improved margins. How the quarter closed on that award — I mean the earlier 2025 award — was largely driven by a greater volume of complex cases under that award, which naturally brought margins down, yet because the price had been locked in during 2025, naturally margins shrank. So my view is that the extra 30% does more than enough to secure a quite healthy margin for us with a big insurer — an indirect insurer, as we mentioned before. So we're really thrilled by what's happened, and our ties with ISSSTELEON grow closer by the day, much more so — plus the NPS we receive from beneficiaries, from ISSSTELEON, is strongly favorable. My sense is that this contract will keep expanding going forward, and so will the award.
Thanks, Suso. There's room for just one or two additional questions. I'm aware of how much time you have, so Joaquin Vero will ask the next one. I've picked up on significant impairment losses when it comes to trade receivables, and that applies not just in Colombia but also in Peru. Could you shed some further light on that?
Absolutely, and thanks for raising that, Joaquin. Regarding the impairment losses in Colombia, I believe we touched on those somewhat in the prior question, so what I'll do now is speak to the situation in Peru. The key point I want to emphasize first is how significant it is that receivable days in Peru came down during Q3 and Q4 of 2025, and we anticipate that improvement carrying forward through 2026, driven by a number of process and system initiatives we're currently deploying, particularly within the receivables cycle. As for why impairment came in higher for Peru in 2025, that's tied more to a specific reconciliation with certain payers dating back to earlier years — services from around 2024 — where we engaged in particular negotiations concerning those services, largely stemming from technology shifts that took place both at the insurance companies and on our side, which caused a delay in collecting on those accounts. That is what drove the impairment impact in Peru specifically during 2025. This is a far more isolated situation, and essentially we'll be addressing those reconciliation effects over the course of the 2026 quarters. Impairment should not be expected to rise above the 2025 levels.
Thanks, Gisele. I believe we can squeeze in one final question, and it's coming from Cesar Piedra. Peru remains the biggest engine of growth for the whole group. When you look at that performance, how much would you call structural as opposed to temporary — whether we're talking about pricing mix, ramp-up effects, or conditions that are unusually favorable?
I'd say I have no trouble at all stating that Peru represents an extremely dependable and steady piece of Auna. It's something we can forecast quite reliably. That makes it hard for me to attach any short-term or out-of-the-ordinary factors to how Peru is doing. In my view, Peru runs almost like a well-oiled machine, built on a highly developed model with strong brands, a medical team that people recognize very well, and our integrated insurance arm, which we run toward an MLR. Once more, that demonstrates a great deal of predictability. So no, apart from some potential gains from Trecca and a few other items down the road, I'd call it a highly stable business carrying very minimal danger of any kind of surprise.
Thanks, Suso. That wrapped up the Q&A portion, so I'll hand things over to you now for your closing comments.
Okay, thanks a lot, everyone. We recognize that 2025 has proven to be a tough year for Auna; the effort has been put in. This was a period of self-examination. It was a stretch marked by substantial work internally. We've laid the groundwork so that growth can resume and continue in 2026 and beyond. My appreciation goes out to the investment community for backing both us and our mission to reshape health care across Latin America. Thanks once more.
This concludes today's conference call. You may now disconnect. Goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Auna S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Auna S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.